Drugs / SUVN-I6107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06705088 | Jan → Dec 2025 | — | Suven Life Sciences Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SUVN-I6107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06705088 ↗ |
| Route | Oral | “single ascending doses administered orally” NCT06705088 ↗ |